Phase i study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

G. K. Schwartz, P. M. Lorusso, M. A. Dickson, S. S. Randolph, M. N. Shaik, K. D. Wilner, R. Courtney, P. J. O'Dwyer

Research output: Contribution to journalArticlepeer-review

225 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)'. Together they form a unique fingerprint.

Medicine & Life Sciences